Clinical Trial Update: Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on pomalidomide for relapsed and refractory multiple myeloma (RRMM).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pomalidomide (Pomalidomide)

Snippet

Sponsor: University of Leeds | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING